Return-On-Investment for Billable Pharmacist-Provided Services in the Primary Care Setting

Abstract

Background:

Pharmacists are increasingly fulfilling roles on primary care teams, yet business models for pharmacist services in these settings have not been optimized. This study describes how an ambulatory care pharmacy department implemented various billing methods to generate revenue for pharmacist services.

Objectives:

(1) Describe pharmacist-delivered billable and non-billable services; and (2) Assess the impact of various billing methods on the return-on-investment (ROI) for billable services.

Methods:

This study was conducted from September 2016 to August 2017 in Virginia. Pharmacist time spent performing billable encounters using current procedural technology (CPT) codes (e.g., incident-to a physician, annual wellness visits) was calculated. Encounters eligible for the hospital-based facility (G0463) and chronic care management (CCM) codes were considered to be potentially billable services. The ROI was calculated for billable and potentially billable services.

Results:

A total of 948.3 hours (0.46 full-time equivalents (FTE)), 17% of all clinical services, were billed using CPT codes. This resulted in a total revenue of $173,638.66. Missed revenue from not billing for the G0463 and CCM codes was $68,268.37. The cost of pharmacist services for 0.46 FTE was $78,613.08, resulting in a ROI for billed pharmacist services of 1.2:1. The ROI increased to 1.6:1 when considering potentially billable services.

Conclusion:

It is feasible to have a positive ROI for billable pharmacist services. To achieve a sustainable business model, there must be a high volume of billable services. G0463 and CCM codes are often underutilized, yet represent significant opportunities in revenue for pharmacist services and should be pursued.

Keywords

pharmacist billing return-on-investment business model primary care

Get full access to this article

View all access options for this article.

References

Centers for Medicare and Medicaid Services. Services of nonphysician personnel furnished incident to physician’s services. In: Medicare Benefit Policy Manual. Revised March 2021. Accessed April 28, 2021. https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/bp102c15.PDF

Snella

Trewyn

Hansen

, et al. Pharmacist compensation for cognitive services: focus on the physician office and community pharmacy. Pharmacotherapy. 2004;24(3):272–388.

American Pharmacists Association. Pharmacists’ patient care services digest. 2016. Accessed April 28, 2021. http://media.pharmacist.com/documents/APhA_Digest.pdf

Sanchev

. Sustainable business models: systematic approach towards successful ambulatory care pharmacy practice. Am J Health Syst Pharm. 2014;71(16):1366–1374.

Kastner

Merk

. Sustaining ambulatory comprehensive medication management practices: perspectives from a Minnesota pharmacist collaborative. J Manag Care Spec Pharm. 2018;24(12):1264–1268.

Dombrowski

Bacci

Klatt

, et al. Key factors for sustainable integration of pharmacists in team-based primary care physician practices. J Am Pharm Assoc (2003). 2019;59(3):439–448.e1.

Isetts

Schondelmeyer

Artz

, et al. Clinical and economic outcomes of medication therapy management services: the Minnesota experience. J Am Pharm Assoc (2003). 2008;48(2):203–211.

Brummel

Lustig

Westrich

, et al. Best practices: improving patient outcomes and costs in an ACO through comprehensive medication therapy management. J Manag Care Spec Pharm. 2014;20(12):1152–1158.

Hoover

Turner

Sampson

, et al. Financial sustainability of an Oregon rural health, primary care, and pharmacist-run comprehensive medication management program through direct medical billing. J Manag Care Spec Pharm. 2020;26(1):30-34.

10.

American Pharmacists Association. Provider status: what pharmacists need to know now. 2013. Accessed June 14, 2020. https://www.pharmacist.com/sites/default/files/files/Provider%20Status%20FactSheet_Final.pdf

11.

Centers for Medicare and Medicaid Services. Addendum A and addendum B updates. 2019. Accessed April 28, 2021. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates.html

12.

Centers for Medicare and Medicaid Services. Chronic care management services. 2016. Accessed April 28, 2021. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/Downloads/ChronicCareManagement.pdf

13.

Centers for Medicare and Medicaid Services. 42 CFR parts 405, 410, 412, et al. Federal Register. 2013;78(237). Accessed April 28, 2021. https://www.govinfo.gov/content/pkg/FR-2013-12-10/pdf/2013-28737.pdf

14.

Centers for Medicare and Medicaid Services. January 2014 update of the hospital outpatient prospective payment system (OPPS). CR 8572. Revised March 25, 2014. Accessed April 28, 2021. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/mm8572.pdf

15.

Fabel

Wagner

Zieglar

, et al. A sustainable business model for comprehensive medication management in a patient-centered medical home. J Am Pharm Assoc (2003). 2019;59(2):285–290.

16.

Thomas

Good

JVR

. Development and implementation of a pharmacist delivered Medicare annual wellness visit at a family practice office. J Am Pharm Assoc (2003). 2014;54(4):427–434.

17.

Hohmann

Hastings

Qian

, et al. Medicare annual wellness visits: a scoping review of current practice models and opportunities for pharmacists. J Pharm Pract. 2020;33(5):666–681.

18.

Musselman

Moczygemba

Pierce

, et al. Development and implementation of clinical pharmacist services within an integrated medical group. J Pharm Pract. 2017;30(1):75–81.

19.

Bureau of Labor Statistics. US Department of Labor. Occupational Employment Handbook. Occupational Employment and Wages. 2016:29–1051.

20.

Rafferty

Yaghoubi

Taylor

, et al. Costs and savings associated with a pharmacists prescribing for minor ailments program in Saskatchewan. Cost Eff Resour Alloc. 2017;15(1):3.

21.

Osae

Rotelli

. Pharmacist-led annual wellness visits: a review. J Pharm Pract. 2021;34(2):295–305.

22.

Isaacs

. The pharmacist’s role in continuous glucose monitoring. Pharm Today. 2020;26(5):37–54.